WilmerHale Advises Visterra in $46.7M Series C Financing

WilmerHale Advises Visterra in $46.7M Series C Financing

Firm News

On October 5, 2017, Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches, announced that it has completed a Series C financing round raising a total of $46.7 million, including a new extension totaling $23.6 million.

The WilmerHale team representing Visterra in this transaction included Lia Der Marderosian, Molly Fox, Emily Gainor and Sam Rothberg.

Visterra's press release is available at www.visterrainc.com.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.